“Global Genomics market set to grow to $23bn by 2022” says new Visiongain report

01 November 2018
Pharma

Visiongain has launched a new pharma report: Global Genomics Market Report 2018-2028: Sequencing, Microarray, PCR, Nucleic Acid Extraction and Purification, Diagnostic Test, Genetic Test, Newborn Screening, Preimplantation Testing, Prenatal Testing, Carrier Testing, Molecular Test, Chromosomal Test, Biochemical Test, Diagnostic, Drug Discovery, Precision Medicine, Research Centers, Hospitals and Clinics, Pharmaceutical Companies and Others.

Genome-based research is already empowering medical researchers to develop improved diagnostics, more effective therapeutic strategies, evidence-based approaches for demonstrating clinical efficacy, and better decision-making tools for patients and providers. The genomics market has been segmented based on technology, test type, method, application, end-user, and geography.

The lead analyst of the report commented "Genomics market is quite fragmented. Companies are investing in research and development activities and the industry growth is highly positive. There is a strong and established customer base for genomics market which is continually progressing. The products are very much undifferentiated as the technological arena is limited to certain extents and, each application segment is demanding technological advancement.

With increasing demand for diagnostic and precision medicines, market players are introducing product developments to differentiate themselves with the best and cost-effective solutions to the market. There is a presence of many domestic and global level players with intense competition among each other."

Leading companies featured in the report include Agilent Technologies, Inc., Danaher Corporation, Eppendorf AG, BGI Genomics Co. Ltd., Eurofins Scientific, GE Healthcare Life Sciences, Illumina, Inc., Oxford Nanopore Technologies Ltd., Qiagen NV, Roche, Thermo Fisher Scientific, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Asthma & COPD Therapies market set to grow to $46bn by 2024” says new Visiongain report

ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.

19 March 2019

Read

“Global Anaesthesia Drugs market set to grow to $11.8bn by 2024” says new Visiongain report

The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.

19 March 2019

Read

“The Global Pharma Contract Sales market will be driven by cost saving and the need for more flexibility” says new Visiongain report

With higher-cost therapies in development, combined with increasing burdens on healthcare budgets from ageing populations and rising disease incidence, market access is becoming more challenging in countries worldwide.

28 February 2019

Read

“Drug Delivery Technologies market set to grow to $355bn by 2024” says new Visiongain report

The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade.

28 February 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1